Drug Profile
Budesonide aerosolised - Pari Pharma
Alternative Names: Buparid; Buparid/PARI SinusLatest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator PARI Pharma GmbH
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rhinosinusitis
Most Recent Events
- 29 Jul 2021 PARI Pharma completes a phase III trial in chronic Rhinosinusitis (NCT01955980) EudraCT2013-002421-30) in Germany
- 05 Oct 2016 Budesonide is still in phase III trials for Rhinosinusitis in Germany (Intranasal, Aerosol) (NCT01955980)
- 01 Apr 2015 Pari Pharma initiates enrolment in a phase I/II trial for Rhinosinusitis in Germany (NCT01955980)